During the course of infection Mycobacterium tuberculosis predominantly resides within macrophages, where it encounters and is often able to resist the antibacterial mechanisms of the host. In this study, we assessed the role of macrophage phospholipases A 2 (PLA 2 s) in defense against M. tuberculosis. Mouse bone marrow-derived macrophages (BMDMs) expressed cPLA 2 -IVA, cPLA 2 -IVB, iPLA 2 -VI, sPLA 2 -IIE, and sPLA 2 -XIIA. The expression of cPLA 2 -IVA was increased in response to M. tuberculosis, gamma interferon, or their combination, and cPLA 2 -IVA mediated the release of arachidonic acid, which was stimulated by M. tuberculosis in activated, but not unactivated, macrophages. We confirmed that arachidonic acid is highly mycobactericidal in a concentration-and pH-dependent manner in vitro. However, when M. tuberculosis-infected macrophages were treated with PLA 2 inhibitors, intracellular survival of M. tuberculosis was not affected, even in inducible nitric oxide synthase-deficient macrophages, in which a major bactericidal mechanism is removed. Moreover, intracellular survival of M. tuberculosis was similar in cPLA 2 -IVA-deficient and wild-type macrophages. Our results demonstrate that the cytosolic PLA 2 s are not required by murine BMDMs to kill M. tuberculosis.
Mycobacterium tuberculosis is an intracellular pathogen that primarily inhabits macrophage phagosomes. In response to M. tuberculosis, macrophages activate antimicrobial pathways which control bacterial replication but are unable to achieve sterilization in vitro (32) .
Only three gamma interferon (IFN-␥)-induced pathways of defense against M. tuberculosis have been defined. These involve inducible nitric oxide synthase (iNOS), phagocyte oxidase (Phox), and the predicted guanosine triphosphatase, LRG-47. Macrophages deficient in iNOS or LRG-47 are defective in their ability to control infection by M. tuberculosis (5, 11, 26, 27) . On the other hand, Phox-deficient macrophages are able to control M. tuberculosis (11, 18, 19) . However, a katG knockout of M. tuberculosis, which is attenuated in wild-type macrophages, returns to virulence in macrophages lacking Phox, indicating that potential antimicrobial mechanisms may be masked by the capacity of M. tuberculosis to detoxify defenses of the host (33) . Previous work from our laboratory has shown that bone marrow derived-macrophages (BMDMs) are able to restrict the growth of M. tuberculosis in an IFN-␥-, iNOS-, and Phox-independent manner (11) . This illustrates that unidentified pathways of host defense against M. tuberculosis are operative in these cells.
Transcriptome analysis of M. tuberculosis within the macrophage phagosome revealed that SigE-dependent genes, involved with the breakdown of fatty acids and resynthesis of cell envelope lipids, were induced in intraphagosomal bacteria (37) . This transcriptional profile could be simulated by the treatment of M. tuberculosis with the cell wall-damaging detergent sodium dodecyl sulfate. Thus, within the phagosome, M. tuberculosis may experience a cell wall-perturbing stress. This observation and others showing that mycobacterial lipids are released within macrophages (3) suggest that macrophages may exert a damaging effect on the lipid-rich M. tuberculosis cell wall. Additionally, several studies have noted that the integrity of the M. tuberculosis cell wall is important for bacterial virulence (6, 9, 16, 35) . This cell wall is likely to be critical in protecting the bacterium against innate defenses.
Phospholipase A 2 (PLA 2 ) enzymes hydrolyze the sn-2 bond of phospholipids to release a free fatty acid and a lysophospholipid. Three classes of PLA 2 s exist in mammals: secreted PLA 2 s (sPLA 2 s), cytosolic PLA 2 s (cPLA 2 s) that are calcium dependent, and cytosolic PLA 2 s that are calcium independent (iPLA 2 s). The cPLA 2 s and iPLA 2 are large (ϳ80 kDa) proteins that reside within the cytosol, whereas sPLA 2 s are smaller (ϳ14 kDa), positively charged proteins that are found in many body tissues and fluids. The sPLA 2 s display potent bactericidal activity (22, 47) , which is dependent on their ability to penetrate the bacterial envelope and hydrolyze phospholipids in the cell membrane (4). Additionally, free fatty acid products of PLA 2 s may be toxic to bacteria or may influence immunity of host cells.
One study concluded that free fatty acid released by cPLA 2 -IVA-killed M. tuberculosis and PLA 2 inhibitors enhanced M. tuberculosis survival in murine peritoneal macrophages (1) . In human-monocyte-derived macrophages, release of arachidonic acid (AA) by cPLA 2 s promoted macrophage apoptosis and consequent killing of M. tuberculosis (8) .
In the present study we reexamined the role of cPLA 2 6 cells/flask in a T75 and were left untreated or were infected with M. tuberculosis at a multiplicity of infection (MOI) of 4:1 for 24 h and activated with 10 ng/ml IFN-␥ for 40 h or with 10 ng/ml IFN-␥ for 16 h followed by infection with M. tuberculosis at 4:1 for 24 h (total time in IFN-␥ was 40 h). The monolayers were then lysed with Trizol (GIBCO BRL) and total RNA was isolated. After treatment with DNase I (Ambion) and purification (QIAGEN RNeasy), 100 ng of RNA was reverse transcribed into cDNA using gene-specific primers and analyzed by PCR on the ABI PRISM 7900HT sequence detection system (Perkin-Elmer). Primers and probes for qRT-PCR were synthesized by Biosearch Technologies. The probes were labeled with the reporter dye FAM at the 5Ј end and Black Hole Quencher at the 3Ј end. The following primer/probe sets were used: sPLA 2 -IIE forward, 5ЈGGATTGGTG TTGTCATGCCC3Ј, reverse, 5ЈGGGTCACAGCCCAGCTTCT3Ј, probe, 5ЈTGA CTGCTGCTATGGCCGCCTG3Ј; sPLA 2 -XIIA forward, 5ЈTAGACACGTACC TCAACGCCG3Ј, reverse, 5ЈTATCCATAGCGTGGAACAGGC3Ј, probe, 5ЈTGC CAGTACAAGTGCAGCGACG3Ј; cPLA 2 -IVA forward, 5ЈCAGCAAAGC ACATCGTGAGTAA3Ј, reverse, 5ЈTTCATTCTCGGTGCCTTTGG3Ј, probe, 5ЈCAGCTCCGACAGTGATGATGAGGCTC3Ј; cPLA 2 -IVB forward, 5ЈAACCTGCCCACTGAGCTGC3Ј, reverse, 5ЈGTGACTCAGAGGCCCAGG G3Ј, probe, 5ЈCCAGCTTCTGTCTGACATTGAGTCCCATG3Ј; iPLA 2 -VI forward, 5ЈGACAGGGACACTGTCTGACCG3Ј, reverse, 5ЈGGCTTCGGGAGC ATCGTAA3Ј, probe, 5ЈCCAGCAGAGCTCCACCTATTCCG3Ј.
Arachidonic acid release. BMDMs were seeded at 1.5 ϫ 10 5 cells/well in 48-well plates and loaded for 14 to 20 h with 0.1 Ci/ml of [ 3 H]arachidonate (Perkin-Elmer). Cells were then washed 3 times with DMEM containing 10% FBS to remove unincorporated arachidonate, and 0.4 ml fresh medium was replaced. Macrophages were then stimulated with phorbol myristate acetate (PMA) (100 nM) and A23187 (2 M) or M. tuberculosis at an MOI of 8:1 with pyrrolidine-2 (10 M) or indoxam (10 M) as indicated. After 6 h the medium was removed and centrifuged to pellet any dislodged cells. An aliquot (0.2 ml) of this medium was submitted to scintillation counting. The cell monolayers were lysed with 0.4 ml H 2 0 containing 0.5% Triton X-100, and 0.2 ml of this was submitted to scintillation counting. The percentage of arachidonate release was calculated as 100 ϫ (disintegrations per minute [dpm] in medium)/(dpm in medium ϩ cell-associated dpm).
Macrophage infections. BMDMs were seeded at 1.5 ϫ 10 5 cells/well in 48-well plates with or without 10 ng/ml murine IFN-␥ (R&D) and 10 ng/ml lipopolysaccharide (LPS) (Sigma). Sixteen hours later, macrophages were infected at an MOI of 4:1. Four hours after infection, extracellular M. tuberculosis was washed out with 1ϫ phosphate-buffered saline; fresh medium was replaced every 36 h. At the time points indicated, macrophages were lysed with H 2 O containing 0.5% Triton X-100, and intracellular bacteria were enumerated by plating serial dilutions of the lysates on agar (Middlebrook 7H11, 10% oleic acid-albumin-dextrose-catalase enrichment; Difco). Inhibitors were added 30 min prior to infection and replaced when fresh medium was added to the wells.
PLA 2 inhibitors. Pyrrolidine-2 (pyrrophenone) and Me-indoxam were prepared as described previously (39, 41) . Arachidonyl trifluoromethyl ketone (ATFMK), bromoenol lactone, and methyl arachidonyl fluorophosphonate (MAFP) were purchased from Cayman Chemical. Quinacrine was purchased from Sigma.
Arachidonic acid treatment of M. tuberculosis. To test the toxicity of AA on M. tuberculosis, early-log-phase M. tuberculosis was diluted to an optical density of 0.05 and exposed in triplicate for 4 h to various concentrations of AA (Sigma) in Middlebrook 7H9 (Difco) supplemented with 0.2% glycerol, 0.2% dextrose, and 0.085% NaCl, with or without 0.5% BSA. After exposure, serial dilutions were plated on agar plates (Middlebrook 7H11, 10% oleic acid-albumin-dextrosecatalase enrichment; Difco).
RESULTS
Expression of PLA 2 s in macrophages. We tested for expression of the known 13 PLA 2 s (cPLA 2 -IVA, cPLA 2 -IVB, iPLA 2 -VI, sPLA 2 -IB, sPLA 2 -IIA, sPLA 2 -IIC, sPLA 2 -IID, sPLA 2 -IIE, sPLA 2 -IIF, sPLA 2 -V, sPLA 2 -X, sPLA 2 -XIIA, and sPLA 2 -XIIB) in BMDMs using RT-PCR. Expression of the following five PLA 2 s was detected: cPLA 2 -IVA, cPLA 2 -IVB, iPLA 2 -VI, sPLA 2 -IIE, and sPLA 2 -XIIA (data not shown). This expression pattern did not alter after treatment of BMDMs with M. tuberculosis, IFN-␥, or the combination of M. tuberculosis and IFN-␥. The remaining eight PLA 2 s that were not found in BMDMs were detected in tissue samples known to express these PLA 2 s (see Materials and Methods), indicating that the PCR primers were functional. A recent study detected sPLA 2 -V protein in peritoneal macrophages by immunohistochemistry, but we did not detect sPLA 2 -V in BMDMs by RT-PCR (36) .
Next, real-time qRT-PCR was performed to study the regulation of PLA 2 s in response to M. tuberculosis, IFN-␥, and their combination. The expression of cPLA 2 -IVA was increased by more than 3-fold after treatment with M. tuberculosis, 8-fold after IFN-␥, and 12-fold after a combination of M. tuberculosis and IFN-␥ (Fig. 1) fold in response to IFN-␥, and restored by the combination of both stimuli (Fig. 1) . No increase in expression of the remaining three PLA 2 s was observed in response to M. tuberculosis, IFN-␥, or the combination (Fig. 1) . AA release. Previous studies have shown that cPLA 2 -IVA has high specificity for AA-containing phospholipids and is the primary PLA 2 involved in the release of AA (42) . Consistent with this, we observed that the cPLA 2 -IVA-specific inhibitor pyrrolidine-2 (14) blocked PMA/A23187-induced AA release, whereas the sPLA 2 inhibitor indoxam did not ( Fig. 2A) . We next sought to determine whether BMDMs released AA after stimulation with M. tuberculosis. Release of AA by unactivated or IFN-␥-activated macrophages in response to M. tuberculosis was not detectable (data not shown). However, a modest statistically significant release of AA in response to M. tuberculosis was observed in macrophages activated with both LPS and IFN-␥ (Fig. 2B) . This release was inhibited by pyrrolidine-2 ( Fig. 2B) , indicating that AA release in response to M. tuberculosis is primarily mediated by cPLA 2 -IVA.
Toxicity of AA towards M. tuberculosis. We next tested whether AA was toxic to M. tuberculosis. Long-chain, unsaturated free fatty acids are known to be potently mycobactericidal (10, (23) (24) (25) . We confirmed that exposure of M. tuberculosis to AA in the absence of BSA resulted in significant killing and showed that this was dependent not only on the concentration of AA but also on the pH of the medium (Fig. 3) . BSA binds free fatty acids. Consistent with this, no killing of M. tuberculosis was observed in the presence of 0.5% BSA (Fig. 3) . Cytosolic PLA 2 s are not required to control M. tuberculosis survival. We next examined whether cPLA 2 -IVA was required for control of M. tuberculosis in BMDMs. Macrophages treated with PLA 2 inhibitors were infected with M. tuberculosis, and the intracellular survival of M. tuberculosis was monitored. The use of the cPLA 2 inhibitor ATFMK or the cPLA 2 -IVA-specific inhibitor pyrrolidine-2 did not affect the survival of M. tuberculosis within unactivated or LPS/IFN-␥-activated macrophages (Fig. 4) . Additionally, no impact on survival of intracellular M. tuberculosis was seen in macrophages treated with the cPLA 2 inhibitor MAFP (10 M) or the sPLA 2 -specific inhibitor Me-indoxam (10 M) (data not shown). The PLA 2 inhibitor quinacrine (5 M) and the iPLA 2 -VI inhibitor bromoenol lactone (10 M) were also tested, but these proved to be toxic to the cells as they drastically altered cellular morphology and disrupted the cell monolayer. Because iNOS-mediated killing of M. tuberculosis might mask a possible role for PLA 2 s, we also tested the PLA 2 inhibitors in iNOS-deficient macrophages (11) . The use of ATFMK, MAFP, pyrrolidine-2, or Me-indoxam did not impact the survival of M. tuberculosis in macrophages lacking iNOS (data not shown). 
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As the cPLA 2 inhibitors may have resulted in incomplete inhibition, macrophages from cPLA 2 -IVA-deficient mice were infected with M. tuberculosis. Unactivated or LPS-and IFN-␥-activated cPLA 2 -IVA-deficient macrophages were able to control M. tuberculosis as well as wild-type macrophages (Fig. 5) . These results indicate that cPLA 2 -IVA is dispensable for BMDM defense against M. tuberculosis.
DISCUSSION
PLA 2 s hydrolyze the sn-2 bond of phospholipids, resulting in the release of free fatty acids and lysophospholipids. PLA 2 s are involved in a range of biological processes, including homeostasis of cell membranes, lipid metabolism, signaling, production of eicosanoids, and host defense (46) . In this study, we observed that BMDMs enhanced the expression of cPLA 2 -IVA in response to M. tuberculosis, IFN-␥, and their combination. cPLA 2 -IVA has a marked specificity for phospholipids with AA at the sn-2 position, and accordingly we were able to block AA release with the cPLA 2 -IVA-specific inhibitor pyrrolidine-2. In addition, sPLA 2 -IIE was upregulated in BMDMs in response to M. tuberculosis, significantly downregulated by IFN-␥, and restored by the combination of both stimuli, a pattern of gene regulation observed for four other genes by microarray analysis (40) . The sPLA 2 s possess potent bactericidal activity, particularly against gram-positive microbes (22) . LPS induced the elevation of sPLA 2 -IIE in alveolar macrophages, suggesting that sPLA 2 -IIE may play an important role in defense against airway pathogens (43) . As alveolar macrophages are one of the first cell types to encounter M. tuberculosis and serve as a bacterial reservoir during the course of the infection, sPLA 2 -IIE may have a function against M. tuberculosis in these cells. In our studies, the sPLA 2 inhibitor indoxam had no impact on survival of M. tuberculosis in BMDMs. This may have been due to poor permeability of the inhibitor toward the macrophages, as seen with an epithelial cell line (30) . In macrophages, however, membrane-impermeant molecules are delivered to phagosomes by pinosomes that fuse with the phagosomes (7). Moreover, indoxam may also be taken up by macrophages during phagocytosis of M. tuberculosis. Upon delivery by either or both routes, indoxam may be able to inhibit phagosomal sPLA 2 s.
In the present study, macrophages activated by LPS and IFN-␥, but not resting macrophages, released AA in response to M. tuberculosis. Macrophage activation may be required to induce signaling pathways that lead to cPLA 2 activity and AA release in culture supernatants. However, it is possible that AA release occurs locally in phagosomes, with only minimal amounts being measured in culture supernatants. In support of this, one study demonstrated that phospholipase activity was enriched in the phagosomes of alveolar macrophages after treatment with Mycobacterium bovis BCG (13). More recently it was shown that cPLA 2 -IVA translocates to phagosomes upon macrophage uptake of yeast particles (15) . Work from the 1940s onwards clearly demonstrated that free fatty acids are highly toxic to mycobacteria (10, (23) (24) (25) . Here, we confirmed that AA is potently mycobactericidal. AA was most toxic at an acidic pH, and it is possible that acidification of the phagosome in activated macrophages may synergize with free fatty acids to kill M. tuberculosis. Free fatty acids possibly embed themselves in the lipid-rich membrane of M. tuberculosis, thereby perturbing its structure and function. Akaki et al. showed that AA released by zymosan-elicited peritoneal macrophages can associate with M. tuberculosis (1) . Additional studies have also demonstrated that macrophages secrete free fatty acids that have mycobactericidal activity (17, 21) . It was speculated that this release might occur via the action of macrophage lipases and could potentially serve as a pathway of mycobacterial control. Along these lines, one study showed that snake venom PLA 2 in combination with macrophage membrane fractions killed M. tuberculosis, indicating that PLA 2 s could release mycobactericidal free fatty acids from membranes (20) . The authors proposed that by localizing to the phagosome, PLA 2 s could hydrolyze toxic free fatty acids from phagosomal membranes and thereby restrict mycobacterial growth. Alternatively, PLA 2 s may directly degrade bacterial membrane phospholipids. For example, a macrophage lysosomal PLA 2 cleaved M. tuberculosis cardiolipin to lysocardiolipin (12) .
Free fatty acids or their downstream products can impact the immune status of host cells. For instance, AA is metabolized into eicosanoids, which serve as important lipid mediators of inflammation, and it is likely that the eicosanoids are instrumental in regulating host immunity during the course of M. tuberculosis infection. Moreover, AA itself promotes phagosome-lysosome fusion, which in turn promotes killing of mycobacteria in macrophages (2) . Administration of AA to M. tuberculosis-infected human macrophages promoted host cell apoptosis and led to a reduction in the mycobacterial burden (8) . Additionally, PLA 2 inhibitors blocked apoptosis of human macrophages and enhanced intracellular survival of the mycobacteria (8) . In our study, we did not observe enhanced viability of M. tuberculosis in macrophages treated with PLA 2 inhibitors or in cPLA 2 -IVA-deficient macrophages. This may be due to different antimycobacterial mechanisms in the human and mouse cells tested, including differences between bacteriostatic and bactericidal effects.
It is possible that the other macrophage-expressed PLA 2 s act redundantly with cPLA 2 -IVA, masking its function. Alternatively, M. tuberculosis may have mechanisms to resist damage induced directly by PLA 2 s or by free fatty acids released by PLA 2 s. Fatty acids may be the primary carbon source for M. tuberculosis during infection (38) . M. tuberculosis within macrophages and mice expressed ␤-oxidation genes involved in fatty acid breakdown and resynthesis (37, 44) . Acetyl coenzyme A utilization is essential for M. tuberculosis pathogenesis, as a mutant lacking the glyoxylate shunt enzymes isocitrate lyase-1 and -2 is attenuated in macrophages and is unable to persist in mice (31) . In addition, M. tuberculosis deficient in SigE, which is required for the transcription of genes involved in fatty acid metabolism, has a reduced level of virulence in both macrophages and mice (28, 29) . The induction of genes involved in fatty acid degradation may not only allow M. tuberculosis to use free fatty acids for energy but may also help detoxify potentially lethal free fatty acids (29) . Thus, ␤-oxidation may serve as a bacterial counterdefense against free fatty acids produced by host cells.
Here we explored the role macrophage PLA 2 s play in host defense against M. tuberculosis. Expression of cPLA 2 IV-A was enhanced in response to M. tuberculosis, IFN-␥, and the combination of M. tuberculosis and IFN-␥, activated macrophages released AA in response to M. tuberculosis, and AA was highly mycobactericidal. Nonetheless, PLA 2 inhibitors did not influence intracellular survival of the bacterium in BMDMs. In addition, cPLA 2 IV-A-deficient BMDMs were able to control M. tuberculosis replication as well as wild-type cells. Our results indicate that cPLA 2 s are not required by mouse BMDMs to kill M. tuberculosis in vitro. Further studies with macrophages deficient in other PLA 2 s or inhibitors specifically targeting other PLA 2 s are needed to explore further the function of these enzymes in host defense against M. tuberculosis.
